Evidence map›Paper›PMID 32731171›Full record

ArticleiScience2020

Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models with 4D Bioprinted Arrays.

Michelle Chadwick, Chen Yang, Liqiong Liu, Christian Moya Gamboa, Kelly Jara, Howon Lee, Hatem E Sabaawy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 85 citations in OpenAlex.

  1. Smart Bioinks for 4D Bioprinting: Requirements, Design, and Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Recent advances in 3D printing applications for CNS tumours.European journal of medical research · 2025
    Review
  19. Review
  20. Harnessing Organoid Platforms for Nanoparticle Drug Development.Drug design, development and therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Michelle ChadwickRutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, USA.
Chen YangDepartment of Mechanical and Aerospace Engineering, Rutgers University - New Brunswick, New Brunswick, NJ 08901, USA.
Liqiong LiuRutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, USA.
Christian Moya GamboaRutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, USA.
Kelly JaraRutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, USA.
Howon LeeDepartment of Mechanical and Aerospace Engineering, Rutgers University - New Brunswick, New Brunswick, NJ 08901, USA. Electronic address: howon.lee@rutgers.edu.
Hatem E SabaawyRutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, USA; Departments of Medicine and Pathology and Laboratory Medicine, RBHS-Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA. Electronic address: sabaawhe@cinj.rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Mechanisms of targeting cellular self-renewal in glioblastomaR01CA226746 · NCI · UNIVERSITY OF COLORADO DENVER · PI SABAAWY, HATIM · 2018 to 2022
$2.3M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA226746
6 · The paper itself

Abstract

Glioblastoma is the most common and deadly primary brain malignancy. Despite advances in precision medicine oncology (PMO) allowing the identification of molecular vulnerabilities in glioblastoma, treatment options remain limited, and molecular assays guided by genomic and expression profiling to inform patient enrollment in life-saving trials are lacking. Here, we generate four-dimensional (4D) cell-culture arrays for rapid assessment of drug responses in glioblastoma patient-derived models. The arrays are 3D printed with thermo-responsive shape memory polymer (SMP). Upon heating, the SMP arrays self-transform in time from 3D cell-culture inserts into histological cassettes. We assess the utility of these arrays with glioblastoma cells, gliospheres, and patient derived organoid-like (PDO) models and demonstrate their use with glioblastoma PDOs for assessing drug sensitivity, on-target activity, and synergy in drug combinations. When including genomic and drug testing assays, this platform is poised to offer rapid functional drug assessments for future selection of therapies in PMO.

Indexed as

CancerMedical BiotechnologyTissue Engineering

Identifiers

PMID32731171
PMCPMC7393526
OpenAlexW3040711420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.